glp 1 and water Electrolytes 101: The Guide for GLP-1 Users – SoWell Dehydration on a GLP-1 is

FTC enforces advertising and endorsement rules, including affiliate disclosure expectations

This is the legal option and the clinically supported option for these goals

Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective owners

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should be counselled about this risk Patient safety advice for those using GLP-1 receptor agonists includes: Report persistent nausea, vomiting, or abdominal pain to your GP promptly Stop treatment and seek urgent medical care if you develop severe, persistent abdominal pain that may suggest pancreatitis Maintain adequate hydration, especially during initial treatment and if experiencing vomiting or diarrhoea Monitor for signs of gallbladder problems (sustained upper right abdominal pain, fever, jaundice) Patients with diabetes should monitor blood glucose levels closely, particularly when starting treatment or adjusting doses Inform healthcare providers of all medications to assess interaction risks Report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app Pregnant women or those planning pregnancy should not use GLP-1 receptor agonists

Wang SY, Zhu S, Wu J, Zhang M, Xu Y, Xu W, et al